AYAytaç Yücel

Aytaç Yücel

*This is an algorithmically generated author record based on publicly available information.

Aytaç Yücel has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Comparison of tocilizumab and intravenous immunoglobulin treatment in intensive care unit patients with covid-19 who developed cytokine storm: a single-center retrospective study

    by Serkan Kalkan, Selcuk Demircan, Zeliha Korkmaz Dişli, Deccane Düzenci, Funda Memişoğlu, Murat Yalçınsoy, Murat Bıçakçıoğlu, Mustafa S. Aydoğan, Zafer Doğan, Aytaç Yücel, et al.

    Aim Coronavirus disease 2019 (COVID-19) may trigger a severe inflammatory response. In the present study, the effects of tocilizumab and intravenous immunoglobulin (IVIG) on mortality in COVID-19 patients with cytokine storms were examined and compared. Methods This retrospective study included all COVID-19 patients who were diagnosed and followed in the intensive care unit between April 2020 and May 2022. The patients were divided into two groups depending on whether they were receiving IVIG or tocilizumab treatment. In addition to the patients’ demographic information, the 28-day mortality was recorded. Their PaO2/FiO2 ratio, CRP, procalcitonin, lymphocyte, ferritin, and D-dimer levels were also recorded before drug administration and on the first day, third day, and first week following the drug administration. Results Of the 73 patients included in this study, 43 (59%) received tocilizumab (Group T), while 30 (41%) received IVIG treatment (Group IVIG). No significant statistical differences were detected between the groups in terms of demographic data, pre-drug inflammatory parameters, improvement in PaO2/FiO2 ratios, and 28-day mortality. The rate of change in CRP levels was significantly higher in Group T than in Group IVIG on day 3 (P = .010) and in the first week (P = .001). The improvement in ferritin levels in the first week was significantly higher in Group T (P = .018). Conclusion No significant difference was detected between the effects of IVIG and tocilizumab on mortality in COVID-19 patients with cytokine storm. However, tocilizumab suppressed inflammation more strongly than IVIG.

  • Open Access

    Preeklampsiye Sekonder Posterior Reversible Ensefalopati Sendromu (PRES): Olgu Sunumu

    by Ökkeş Hakan Mi̇ni̇ksar, Aytaç Yücel, Mustafa Said Aydoğan, Füsun Kaya, Türkan Toğal

    Posterior reversible ensefalopati sendromu (PRES) baş ağrısı, değişken mental bozukluk, epilepsi ve görme bozukluğu ile karakterize olup sıklıkla ani olarak yükselen ve kompanse edilemeyen arter basıncına bağlı olarak gelişir ve tanı klinik ve radyolojik olarak konulabilir. Bu hastalarda beyaz cevher ile birlikte gri cevher tutulumunun da olması nedeniyle 1996 yılında ilk olarak tanımlanan Posterior Reversibl Lökoansefalopati yerine günümüzde PRES terimi kullanılmaktadır. PRES’in erken teşhisi ve tedavisi oldukça önemlidir. Aksi takdirde kalıcı beyin hasarına ve kronik epilepsi gibi nöro­lojik sekellere neden olabilir. Bu makalede, preeklampsi ön tanısı olan 36 haftalık bir gebede postpartum dönemde klinik ve nöroradyolojik bulguları ile PRES tanısı konulan olgu sunulmaktadır.

  • Effects of Oral β- Glucan on Liver Ischemia/Reperfusion Injury in Rats

    by M.S. Aydogan, A. Yucel, M.A. Erdogan, A. Polat, A. Cetin, M. Ucar, Z.R. Duran, C. Colak, M. Durmus